From

Institution

Field

Type

Open access only Cited by patents (Lens) Include non-Aachen papers (citing/cited)

Reset

Papers matching “nivolumab” 115

Sort: Relevance Cited Newest Oldest Fwci Patents ⇩ CSV

Not finding it? Sign in to also search OpenAlex live.

Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol
2024 BMC Cancer article Medicine Cancer Immunotherapy and Biomarkers Open access

Brigit van Dijk, Karlijn de Joode, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Christian U. Blank, M. J. Boers‐Sonderen, +15 more

7

citations
OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117)
2026 British Journal of Cancer article Medicine Cancer Immunotherapy and Biomarkers Open access

Viktor Grünwald, Jurgen Alt, Mareike Tometten, Mathias Hänel, Philipp Ivanyi, Gunter Schuch, +7 more

0

citations
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
2024 Nature Medicine article Medicine Cancer Immunotherapy and Biomarkers Open access

Iris Nederlof, Olga I. Isaeva, Manon de Graaf, R. Gielen, Noor A. M. Bakker, A.L. Rolfes, +32 more

74

citations
1140TiP Safe stop IPI-NIVO trial: Early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab
2024 Annals of Oncology article Medicine Cancer Immunotherapy and Biomarkers Open access

Brigit van Dijk, Karlijn de Joode, MJB Aarts, Franchette W.P.J. van den Berkmortel, C.U. Blank, M. J. Boers‐Sonderen, +13 more

0

citations
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
2022 Annals of Oncology article Medicine Occupational and environmental lung diseases Open access

Solange Peters, Arnaud Scherpereel, Robin Cornelissen, Youssef Oulkhouir, Laurent Greillier, Kaplan Ma, +12 more

266

citations
First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743
2022 Lung Cancer article Medicine Occupational and environmental lung diseases Open access

Arnaud Scherpereel, Scott Joseph Antonia, Francesco Grossi, Dariusz Mirosław Kowalski, Gérard Zalcman, Anna K. Nowak, +10 more

31

citations
Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial
2022 The Lancet Healthy Longevity article Medicine Cancer Immunotherapy and Biomarkers Open access

Matthias P A Ebert, Nadja M. Meindl‐Beinker, Tobias Gutting, Martin Maenz, Johannes Betge, Nadine Schulte, +16 more

31

citations
Adjuvant nivolumab after chemoradiotherapy and resection for patients with esophageal cancer: A real‐world matched comparison of overall survival
2025 International Journal of Cancer article Medicine Esophageal Cancer Research and Treatment Open access

Rob H.A. Verhoeven, Steven C. Kuijper, Marije Slingerland, Bas P. L. Wijnhoven, Mark I. van Berge Henegouwen, Peter S.N. van Rossum, +4 more

4

citations
Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer
2022 European Urology article Medicine Bladder and Urothelial Cancer Treatments Open access

Ben-Max de Ruiter, Jons Wouter van Hattum, Djoeri Lipman, Theo M. de Reijke, R. Jeroen A. van Moorselaar, Erik J. van Gennep, +7 more

30

citations
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743
2026 Journal of Clinical Oncology article Medicine Occupational and environmental lung diseases Open access

Arnaud Scherpereel, Paul Baas, Anna K. Nowak, Anne S. Tsao, Nobukazu Fujimoto, Solange Peters, +14 more

8

citations
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
2022 Nature Medicine article Medicine Cutaneous Melanoma Detection and Management Open access

Irene L. M. Reijers, Alexander Maxwell Menzies, Alexander C. J. van Akkooi, Judith M. Versluis, N.M.J. Van Den Heuvel, Robyn P.M. Saw, +31 more

378

citations
ISA101 and nivolumab for HPV-16 + cancer: updated clinical efficacy and immune correlates of response
2022 Journal for ImmunoTherapy of Cancer article Medicine Cancer Immunotherapy and Biomarkers Open access

Luana Guimarães de Sousa, Kimal Rajapakshe, Jaime Rodriguez Canales, Renee L. Chin, Lei Feng, Qi Wang, +12 more

98

citations
Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands
2023 Journal of Immunotherapy article Medicine Cancer Immunotherapy and Biomarkers Open access

Michiel C.T. van Zeijl, Jesper van Breeschoten, Liesbeth C. de Wreede, Michel W.J.M. Wouters, Doranne L. Hilarius, Christian U. Blank, +14 more

25

citations
Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care
2020 Translational Lung Cancer Research article Medicine Cancer Immunotherapy and Biomarkers Open access

Robert D. Schouten, Lucie Egberink, Mirte Muller, Cornedine Jannette de Gooijer, Erik D. van Werkhoven, Michel M. van den Heuvel

11

citations
Combination of nivolumab with standard induction chemotherapy in children and adults with EBV-positive nasopharyngeal carcinoma
2024 HNO article Medicine Head and Neck Cancer Studies Open access

Tristan Römer, Christian Vokuhl, Gundula Staatz, Felix Manuel Mottaghy, Hans Christiansen, Michael J. Eble, +9 more

5

citations
Retreatment With Nivolumab and Ipilimumab in Pleural Mesothelioma Following Disease Progression After a Durable Response: Case Series
2025 JTO Clinical and Research Reports article Medicine Occupational and environmental lung diseases Open access

Illaa Smesseim, Jacobus A. Burgers

1

citations
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
2024 New England Journal of Medicine article Medicine Cutaneous Melanoma Detection and Management Open access

Christian U Blank, Minke W Lucas, Richard A. Scolyer, Bart A. van de Wiel, Alexander Maxwell Menzies, Marta López‐Yurda, +62 more

538

citations
Model-Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness
2026 Clinical Pharmacokinetics article Medicine Cancer Immunotherapy and Biomarkers Open access

Yan Wang, Laura H. Bukkems, Rob ter Heine, J G Coen van Hasselt, Stijn L.W. Koolen, Jeroen J. M. A. Hendrikx, +10 more

1

citations
Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial
2025 Nature Medicine article Medicine Nonmelanoma Skin Cancer Studies Open access

Sabine E. Breukers, Joleen J.H. Traets, Stan W. van Dijk, Itske Fraterman, Robert D. Crommelin, Hedda J. van der Hulst, +42 more

16

citations
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
2024 Clinical Cancer Research article Medicine Cancer Immunotherapy and Biomarkers Open access

Laurien Joanna Zeverijn, Birgit S. Geurts, Thomas Battaglia, Jade M. van Berge Henegouwen, Gijs F. de Wit, Louisa Rose Hoes, +21 more

7

citations
Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancer
2023 Tumor Biology article Medicine Cancer Immunotherapy and Biomarkers Open access

Mirte Muller, Myron G. Best, Vincent van der Noort, T. Jeroen N. Hiltermann, Anna-Larissa Nadia Niemeijer, Nik Sol, +13 more

4

citations
Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma
2021 Nature Communications article Medicine Cancer Immunotherapy and Biomarkers Open access

Joris L. Vos, Joris B.W. Elbers, Oscar Krijgsman, Joleen J.H. Traets, Xiaohang Qiao, Anne M. van der Leun, +28 more

330

citations
Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma
2025 Communications Medicine article Medicine Cancer Immunotherapy and Biomarkers Open access

Judith M. Versluis, Huma Shehwana, Robert Elens, Alexander Maxwell Menzies, Irene L. M. Reijers, Petros Dimitriadis, +10 more

6

citations
Activation of CD8⁺ T Cells in the Human Ex Vivo Lung Tumor Microenvironment Using Anti‐CD3/CD28 and Nivolumab
2025 European Journal of Immunology article Medicine Cancer Immunotherapy and Biomarkers Open access

Tonia Bargmann, Sebastian Konzok, Renato Liguori, Charline Sommer, Dirk Schaudien, Charlotte Schob, +9 more

4

citations
Long-term outcomes of preoperative nivolumab with or without relatlimab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung)
2025 European Journal of Cancer article Medicine Cancer Immunotherapy and Biomarkers Open access

Kristof Cuppens, Marcel Wiesweg, Brigitte Maes, Bert Du Pont, Till Ploenes, Dirk Theegarten, +7 more

3

citations